MAP2K7 and neoplasm: Regardless of the type of treatment (i.e., single agent or combined therapy), the BRAF/MEK inhibitor therapy is associated with a response rate of almost 100% with a tumor volume reduction ranging from 80–90% after 3–4 months of treatment.